Pancreatic cancer: identifying key drivers and drug testing in a clinically relevant model, based on tumor biology

The current project aims to unravel in both models the key drivers for aggressive pancreatic cancer. In addition, we will focus on repurposing of drugs selected
against complementary pathways and use the PDTX model for testing of drug combinations in a panel of tumors from different patients. This protocol should enable a rapid clinical translation to personalized therapy options in this devastating cancer.